In 2006, the number of the registry for institutions was 352 and cases were 22,005. The number of institutions in this prognostic study was 134 and cases were 8788, with 39.9 %. An assessment of 5-year prognosis for cases registered in 2006 has been carried out, and here we report the results thanks to a number of efforts and cooperation. We believe that it is necessary to further promote the registry for contributions to improving breast cancer care and prognosis.
Background characteristics of the patients are summarized in Table 1 . The 5-year disease-free survival (DFS) was Electronic supplementary material The online version of this article (doi:10.1007/s12282-015-0646-3) contains supplementary material, which is available to authorized users. N3 metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node involvement OR Metastases in clinically detected ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases OR Metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement. P values were calculated using the log rank test Tumor size is a marker of invasiveness. P values were calculated using the log rank test 93.5 %, and the 5-year overall survival (OS) was 92.7 % at a median follow-up of 60.0 months (range 0.0-60.0). The TNM classification and histological classification were registered according to the UICC staging [1] and WHO classification systems [2] , respectively. The present report includes age-and subtype-based analyses in addition to the traditional TNM classification-based analyses. In addition to TNM classifications, estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) statuses, which are strong prognostic factors, have become frequently used to determine the therapeutic strategy in the clinical setting. Note that during the study period, not only the cutoff level of ER, PgR and HER2 positivity, but also test procedures for immunostaining and HER2 gene amplification have not yet been standardized, and trastuzumab had been gradually spread in daily clinic in Japan. For ER-negative/HER2-positive patients, DFS improved from 85.0 % in 2004 to 90.9 % in 2006, and OS from 85.02 to 89.88 %, respectively.
We appreciate the considerable support that we have received and would like to ask for continuing understanding and support of the registry. The TNM classification was identified by the UICC staging system ER estrogen receptor, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2
